Rocconi et al. analyse gene expression data from patients with ovarian cancer receiving the autologous tumor cell immunotherapy gemogenovatucel-T (Vigil) as part of the VITAL study. The authors identify ENTPD1/CD39 expression as a predictor of relapse-free and overall survival benefit.
- Rodney P. Rocconi
- Laura Stanbery
- John Nemunaitis
